<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660618</url>
  </required_header>
  <id_info>
    <org_study_id>201702725</org_study_id>
    <nct_id>NCT03660618</nct_id>
  </id_info>
  <brief_title>LSFG-SKIN, Laser Speckle Flowgraphy</brief_title>
  <official_title>LSFG-SKIN, Laser Speckle Flowgraphy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to quantify normal and abnormal skin blood flow regionally in
      different areas of the body(face, extremities, over burns and wounds) at baseline and over
      time in response to treatment or environmental changes, such as temperature, light and
      pressure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laser speckle skin blood flow (LSFG-SKIN) will be recorded in normal subjects and in patients
      with disorders affecting skin capillary perfusion, which may include cardiovascular
      disorders, dermatologic disorders, skin wounds, ocular disorders, psychiatric disorders, and
      neurologic disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">March 2, 2018</completion_date>
  <primary_completion_date type="Actual">March 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laser Speckle Skin Blood Flow</measure>
    <time_frame>30 minutes</time_frame>
    <description>explore how spatial and temporal variations in skin blood flow reveal the status of stated systems.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypertension</condition>
  <condition>Heart Failure</condition>
  <condition>Vascular Ischemia</condition>
  <condition>Burns</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Radiation Injuries</condition>
  <condition>Uveitis</condition>
  <condition>Scleritis</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Autonomic Neuropathy</condition>
  <condition>Stroke</condition>
  <condition>Intracranial Hemorrhages</condition>
  <condition>TIA</condition>
  <condition>Migraine</condition>
  <condition>Headache</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Clinic Subjects</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cardiology subjects, dermatology subjects, endocrine subjects, neurology subjects, psychiatry subjects, surgery subjects, ophthalmology subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>laser speckle flowgraphy</intervention_name>
    <description>blood flow state of the skin as real time two dimensional image</description>
    <arm_group_label>Clinic Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Controls

        ‚óèHealthy normal control subjects ages 18-90

        Cardiology Subjects

          -  Ages 18-90

          -  History of dysrhythmia, heart failure, cardiac ischemia, hypertension, peripheral
             vascular disease

        Dermatology Subjects

          -  Ages 18-90

          -  History of inflammatory and cancerous lesions

        Endocrine Subjects

          -  Ages 18-90

          -  History of diabetes, thyroid disease

        Neurology Subjects

          -  Ages 18-90

          -  History of dementia, headaches, Parkinson's, light sensitivity, stroke, TIA, multiple
             sclerosis

        Psychiatry Subjects

          -  Ages 18-90

          -  History of bipolar, schizophrenia, anxiety, depression

        Surgery Subjects

          -  Ages 18-90

          -  History of skin wounds(trauma, chemotherapy, radiation), thermal burns, or plastic and
             reconstructive surgical procedures.

        Ophthalmology Subjects

          -  Ages 18-90

          -  History of ocular disorders caused by hypo perfusion or inflammatory disorders

        Exclusion Criteria:

        Controls

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Cardiology Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

             3. Dermatology Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Endocrine Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Neurology Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Psychiatry Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Surgery Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma

        Ophthalmology Subjects

          -  Cataract or media opacity that would degrade the imaging of the retina. Mild cataracts
             are okay.

          -  Angle closure glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Iowa Department of Ophthalmology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 5, 2018</last_update_submitted>
  <last_update_submitted_qc>September 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Randy Kardon</investigator_full_name>
    <investigator_title>Randy Kardon M.D. Ph.D Professor and Director of Neuro-ophthalmology</investigator_title>
  </responsible_party>
  <keyword>perfusion</keyword>
  <keyword>inflammatory</keyword>
  <keyword>ischemia</keyword>
  <keyword>lesions</keyword>
  <keyword>neuropathy</keyword>
  <keyword>burns</keyword>
  <keyword>cancer</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Scleritis</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 7, 2019</submitted>
    <returned>May 28, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

